About CLINUVEL

Dr Dennis Wright

BPharm MSc PhD

Acting Chief Scientific Officer

Dr Wright has a broad range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager.

During this time Dr Wright was responsible for the registration of a number of key products in Australia and the management of regulatory strategy for development projects.

Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen (ASX:HGN).

He has a Pharmacy degree and post-graduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne. Dr Wright is responsible for leading the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.

Latest Company Announcements

31 January 2017

Appendix 4C - Quarterly report

Quarterly report

Read More
23 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
20 December 2016

CLINUVEL Newsletter - December 2016

At the end of a calendar year we look back on plenty of activities and a solid financial performance by the CLINUVEL Group.

Read More
12 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
28 November 2016

Results of Meeting

AGM results

Read More
27 November 2016

Chair's Address to the Annual General Meeting

I would like to commence my address by saying it is always a pleasure to welcome familiar and a few new faces to the CLINUVEL Annual General meeting.

Read More

Quick Links